The problem
The Union Health Ministry released the National Health Accounts estimates for 2022-23 on 27 May 2026. They put out-of-pocket spending at 43.4% of total health expenditure in 2022-23, down from 64.2% in 2013-14. The same release says the share had dipped to 39.4% in 2021-22, which it ties to one-time government spending during the pandemic, so the 2022-23 figure is higher than the year before. A 2025 peer-reviewed paper in Frontiers in Public Health says, citing earlier studies, that medicines are the largest part of this burden, and more than half of household healthcare spending in some states.
The government's answer is the Jan Aushadhi scheme. The Ministry of Chemicals and Fertilizers described the pricing principle in 2022 as follows: a medicine is priced at no more than half the average price of the top three brands. The ministry said then that its medicines are cheaper at least by 50% and in some cases by 80% to 90%. A PIB backgrounder in March 2026 said over 18,000 Kendras sell generics generally 50-80% lower than comparable branded medicines. The same Frontiers paper compared 696 eye and ENT products, with brand prices from late 2021. The paper reports the Jan Aushadhi price for eye medicines as 69 percent higher than branded drugs, in a section on the minimum branded price, without saying how the figure was calculated. The ENT comparison covered seven Jan Aushadhi drugs and 137 brands. Its authors wrote that not all generic drugs are uniformly cheaper than their branded counterparts. The paper's abstract also says most of the Jan Aushadhi medicines it examined met the WHO affordability threshold, while chronic treatments such as glaucoma drugs remained a burden for low-income households. That is one study, mostly of eye and ENT products, not a finding about all medicines.
The Solved elsewhere tab describes a government app for finding generics. The PIB backgrounder does not say whether it matches the brand written on a prescription, so we cannot say whether it helps a patient with a prescription find the matching generic.
We compiled this page from public sources. We did not contact the Pharmaceuticals and Medical Devices Bureau of India, the Health Ministry or the paper's authors. We did not compare any prices ourselves or visit a Kendra, so we have not checked whether one stocks a given medicine. The 50-80% and 18,000 figures are the government's own and were not independently checked. This page is not medical advice.
- Who has this problem
- Households that pay for medicines out of their own pocket.
Where the demand comes from
What people do today
- The workaround
- The government offers Jan Aushadhi Kendras, which sell generics at prices it says are generally 50-80% lower than comparable branded medicines (PIB, March 2026).
- Why that fails
- One 2025 paper comparing eye and ENT products reports the Jan Aushadhi price for eye medicines as 69 percent higher than branded drugs, using 2021 brand prices and without saying how the figure was calculated. It also says most of the Jan Aushadhi medicines it examined met the WHO affordability threshold.
How others solved it2
Products and services that work on a similar problem, in India and elsewhere.
- Jan Aushadhi KendrasIndia
Stores run under the government's PMBJP scheme, implemented by the Pharmaceuticals and Medical Devices Bureau of India. PIB said in March 2026 that over 18,000 Kendras sell generics generally 50-80% lower than comparable branded medicines. These are government figures. A 2025 paper reports a higher Jan Aushadhi price for the eye medicines it compared.
- Jan Aushadhi Sugam appIndia
PIB said in March 2026 that this free Android and iOS app, launched in 2019, finds the nearest Kendra, searches generic medicines with real-time availability, and compares Jan Aushadhi MRPs with branded alternatives. The backgrounder does not say whether it matches the brand written on a prescription. We have not tested it.
Read and watch4
Where the facts on this page come from.
- ArticleUnion Health Ministry Releases The National Health Accounts Estimates for India 2022-23
Ministry of Health and Family Welfare, via PIB, 27 May 2026
- ArticleMedicine affordability and access in India: lessons from generic-branded price variation under the Jan Aushadhi Scheme
Frontiers in Public Health, 5 December 2025 (via PubMed Central)
- ArticleGap in Price of Branded and Janaushadhi Medicine
Ministry of Chemicals and Fertilizers, via PIB, 11 February 2022
- ArticlePIB Backgrounder: Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)
PIB, 7 March 2026
